$3.9 Billion in New Priorities for Stem Cell and Genetic Research Trigger Reshuffle at California Agency
Goals include breaking down silos, improving data access and preclinical work
California’s $12 billion stem cell and gene therapy agency is reshuffling its top management to beef up its performance on sweeping new priorities for its last $3.9 billion in research funding.
The moves are also aimed at dealing with the deficiencies cited in the agency’s most recent performance audit, which identified problems ranging from employee morale and an excessively large governing board to pay inequality and royalty income issues.
The coming changes were disclosed in a reorganization plan to be presented Thursday to the Governance Subcommittee of the board of the California Institute for Regenerative Medicine (CIRM), as the research agency is formally known.
In a slide presentation posted online, CIRM’s “new” CEO and President Jonathan Thomas said the overhaul is aimed
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.